GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Panacea Life Sciences Holdings Inc (OTCPK:PLSH) » Definitions » Enterprise Value

PLSH (Panacea Life Sciences Holdings) Enterprise Value : $23.79 Mil (As of Dec. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Panacea Life Sciences Holdings Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Panacea Life Sciences Holdings's Enterprise Value is $23.79 Mil. Panacea Life Sciences Holdings's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $-4.46 Mil. Therefore, Panacea Life Sciences Holdings's EV-to-EBIT ratio for today is -5.33.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Panacea Life Sciences Holdings's Enterprise Value is $23.79 Mil. Panacea Life Sciences Holdings's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.87 Mil. Therefore, Panacea Life Sciences Holdings's EV-to-EBITDA ratio for today is -8.30.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Panacea Life Sciences Holdings's Enterprise Value is $23.79 Mil. Panacea Life Sciences Holdings's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $4.14 Mil. Therefore, Panacea Life Sciences Holdings's EV-to-Revenue ratio for today is 5.75.


Panacea Life Sciences Holdings Enterprise Value Historical Data

The historical data trend for Panacea Life Sciences Holdings's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Life Sciences Holdings Enterprise Value Chart

Panacea Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Enterprise Value
- - 18.91 24.18

Panacea Life Sciences Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.14 24.18 25.36 25.51 24.79

Competitive Comparison of Panacea Life Sciences Holdings's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panacea Life Sciences Holdings's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Panacea Life Sciences Holdings's Enterprise Value falls into.



Panacea Life Sciences Holdings Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Panacea Life Sciences Holdings's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Panacea Life Sciences Holdings's Enterprise Value for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Panacea Life Sciences Holdings  (OTCPK:PLSH) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Panacea Life Sciences Holdings's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=23.791/-4.461
=-5.33

Panacea Life Sciences Holdings's current Enterprise Value is $23.79 Mil.
Panacea Life Sciences Holdings's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.46 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Panacea Life Sciences Holdings's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=23.791/-2.866
=-8.30

Panacea Life Sciences Holdings's current Enterprise Value is $23.79 Mil.
Panacea Life Sciences Holdings's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.87 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Panacea Life Sciences Holdings's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=23.791/4.139
=5.75

Panacea Life Sciences Holdings's current Enterprise Value is $23.79 Mil.
Panacea Life Sciences Holdings's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Panacea Life Sciences Holdings Enterprise Value Related Terms

Thank you for viewing the detailed overview of Panacea Life Sciences Holdings's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Panacea Life Sciences Holdings Business Description

Traded in Other Exchanges
N/A
Address
5910 S University Boulevard, C18-193, Greenwood Village, CO, USA, 80121
Panacea Life Sciences Holdings Inc is a holding company organized as a plant-based natural health ingredient and product company, specializing in the development, manufacturing, research, and distribution of products and rapidly growing natural health and wellness market segment for both humans and animals. Its products are CBD Softgels, CBD Tablets, CBD Topicals, CBD Skin Care, CBD Tinctures, CBD Edibles, CBD Patches, CBD Pets, and PPE.
Executives
Leslie Buttorff director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER 16194 W 45TH DRIVE, GOLDEN CO 80403
Janice Nerger director 5910 S UNIVERSITY BLVD., C18-193, GREENWOOD VILLAGE CO 80121
Nathan Joel Berman officer: CONTROLLER & PRIN ACTNG OFCR 16194 W 45TH DRIVE, GOLDEN CO 80403
22nd Century Group, Inc. 10 percent owner 8560 MAIN STREET, SUITE 4, WILLIAMSVILLE NY 14221
Harvey J Kesner 10 percent owner 65 E. 55TH STREET, NEW YORK NY 10022
Lawrence Wert director 170 NUTTALL RD, RIVERSIDE IL 60546
Chesne Derek Du officer: Chief Growth Officer 80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Alvaro Daniel Alberttis director 80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Vladislav Yampolsky director, 10 percent owner 332 PLAZA REAL, BOCA RATON FL 33432
Steven A Schwartz director 332 PLAZA REAL, BOCA RATON FL 33432
Andrew L. Johnson officer: Chief Strategy Officer 80 NE 4TH AVE. SUITE 28, DELRAY BEACH FL 33483
Emiliano Angel Aloi officer: President 510 SUNSHINE DRIVE, DELRAY BEACH FL 33444
Jonathan Gilbert director, officer: Executive Chairman 36 SYCAMORE LANE, ROSALYN HEIGHTS NY 11577
John C Price director 4721 IRONTON STREET, BUILDING A, DENVER CO 80239
Kevin James Esval director NEURO HITECH INC, ONE PENN PLAZA STE 1503, NEW YORK NY 10019

Panacea Life Sciences Holdings Headlines

From GuruFocus

Panacea Announces Letter of Intent to Acquire N7 Enterprises, Inc.

By Stock market mentor Stock market mentor 01-23-2023